{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:34:27Z","timestamp":1792802067526,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Clinical Research Support Fee of Jichi Medical University Hospital","award":["2018-3, 2019-3"],"award-info":[{"award-number":["2018-3, 2019-3"]}],"id":[{"id":"https:\/\/ror.org\/04at0zw32","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17H04286"],"award-info":[{"award-number":["17H04286"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intraperitoneal (IP) administration of paclitaxel (PTX) has a great pharmacokinetic advantage to control peritoneal lesions and can be combined with various systemic chemotherapies. In this study, we evaluate the efficacy and tolerability of a combination of IP-PTX and systemic S-1\/oxaliplatin (SOX) for induction chemotherapy for patients with peritoneal metastases (PM) from gastric cancer (GC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Patients with GC who were diagnosed as macroscopic PM (P1) or positive peritoneal cytology (CY1) by staging laparoscopy between 2016 and 2019 were enrolled. PTX was IP administered at 40\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on days 1 and 8. Oxaliplatin was IV administered at 100\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on day 1, and S-1 was administered at 80\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day for 14 consecutive days, repeated every 21\u00a0days. Survival time and toxicities were retrospectively explored.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-four patients received SOX\u2009+\u2009IP-PTX with a median (range) of 16 (1\u201348) courses, although oxaliplatin was suspended due to the hematotoxicity or intolerable peripheral neuropathy in many patients. The 1-year overall survival (OS) rate was 79.5% (95% CI 64.4\u201388.8%) with median survival time of 25.8\u00a0months. Gastrectomy was performed in 20 (45%) patients who showed macroscopic shrinkage of PM with a 1-year OS rate of 100% (95% CI 69.5\u2013100%). Grade 2 and 3 histological responses was achieved in four (20%) and one (5%) patients. Grade 3\/4 toxicities included neutropenia (11%), leukopenia (39%), and anemia (14%). There were no treatment-related deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Combination chemotherapy using SOX\u2009+\u2009IP-PTX regimen is highly effective and recommended as induction chemotherapy for patients with PM from GC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-020-09388-4","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T10:08:45Z","timestamp":1606990125000},"page":"3863-3870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Oxaliplatin as Induction Therapy for Patients with Advanced Gastric Cancer with Peritoneal Metastases"],"prefix":"10.1245","volume":"28","author":[{"given":"Shin","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Ohzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyo","family":"Miyato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihito","family":"Kanamaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kurashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan Kawarai","family":"Lefor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Sata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5708-7130","authenticated-orcid":false,"given":"Joji","family":"Kitayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"issue":"1","key":"9388_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-012-0163-4","volume":"16","author":"A Nashimoto","year":"2013","unstructured":"Nashimoto A, Akazawa K, Isobe Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16(1):1\u201327.","journal-title":"Gastric Cancer."},{"issue":"1","key":"9388_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejso.2013.10.019","volume":"40","author":"F Coccolini","year":"2014","unstructured":"Coccolini F, Cotte E, Glehen O, et al. Intraperitoneal chemotherapy in advanced gastric cancer meta-analysis of randomized trials. Eur J Surg Oncol. 2014;40(1):12\u201326.","journal-title":"Eur J Surg Oncol."},{"issue":"33","key":"9388_CR3","doi-asserted-by":"publisher","first-page":"7478","DOI":"10.3748\/wjg.v22.i33.7478","volume":"22","author":"J Wei","year":"2016","unstructured":"Wei J, Wu ND, Liu BR. Regional but fatal: intraperitoneal metastasis in gastric cancer. World J Gastroenterol. 2016;22(33):7478\u201385.","journal-title":"World J Gastroenterol."},{"issue":"3","key":"9388_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215\u201321.","journal-title":"Lancet Oncol."},{"issue":"4","key":"9388_CR5","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/annonc\/mdn717","volume":"20","author":"YK Kang","year":"2009","unstructured":"Kang YK, Kang WK, Shin DB, et al. Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666\u201373.","journal-title":"Ann. Oncol."},{"issue":"31","key":"9388_CR6","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991\u201397.","journal-title":"J Clin Oncol."},{"issue":"1","key":"9388_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36\u201346.","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"9388_CR8","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1093\/annonc\/mdn403","volume":"19","author":"SE Al-Batran","year":"2008","unstructured":"Al-Batran SE, Hartmann JT, Hofheinz R, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008;19(11):1882\u201387.","journal-title":"Ann. Oncol."},{"issue":"3","key":"9388_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/02841860600791483","volume":"46","author":"SY Oh","year":"2007","unstructured":"Oh SY, Kwon HC, Seo BG, Kim SH, Kim JS, Kim HJ. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Acta Oncol. 2007;46(3):336\u201341.","journal-title":"Acta Oncol."},{"issue":"3","key":"9388_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10120-009-0517-8","volume":"12","author":"M Imazawa","year":"2009","unstructured":"Imazawa M, Kojima T, Boku N, et al. Efficacy of sequential methotrexate and 5-fluorouracil (MTX\/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination. Gastric Cancer. 2009;12(3):153\u201357.","journal-title":"Gastric Cancer."},{"issue":"10","key":"9388_CR11","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/jjco\/hyt114","volume":"43","author":"K Shirao","year":"2013","unstructured":"Shirao K, Boku N, Yamada Y, et al. Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 2013;43(10):972\u201380.","journal-title":"Jpn J Clin Oncol."},{"key":"9388_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53\u201363.","journal-title":"Cancer Treat. Res."},{"issue":"9","key":"9388_CR13","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","volume":"17","author":"O Glehen","year":"2010","unstructured":"Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370\u201377.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"9388_CR14","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"XJ Yang","year":"2011","unstructured":"Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575\u201381.","journal-title":"Annals of surgical oncology."},{"issue":"8","key":"9388_CR15","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.ejso.2016.03.016","volume":"42","author":"Y Yonemura","year":"2016","unstructured":"Yonemura Y, Canbay E, Li Y, et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol. 2016;42(8):1123\u201331.","journal-title":"Eur J Surg Oncol."},{"issue":"9","key":"9388_CR16","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3748\/wjg.v12.i9.1412","volume":"12","author":"M Kobayashi","year":"2006","unstructured":"Kobayashi M, Sakamoto J, Namikawa T, et al. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol. 2006;12(9):1412\u201315.","journal-title":"World J Gastroenterol."},{"issue":"9","key":"9388_CR17","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","volume":"10","author":"M Markman","year":"1992","unstructured":"Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol. 1992;10(9):1485\u201391.","journal-title":"J Clin Oncol."},{"issue":"12","key":"9388_CR18","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.1995.13.12.2961","volume":"13","author":"P Francis","year":"1995","unstructured":"Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol. 1995;13(12):2961\u201367.","journal-title":"J Clin Oncol."},{"issue":"4","key":"9388_CR19","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(4):1001\u201307.","journal-title":"J Clin Oncol."},{"issue":"1","key":"9388_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34\u201343.","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"9388_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/annonc\/mdp260","volume":"21","author":"H Ishigami","year":"2010","unstructured":"Ishigami H, Kitayama J, Kaisaki S, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21(1):67\u201370.","journal-title":"Ann. Oncol."},{"issue":"18","key":"9388_CR22","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1002\/cncr.28204","volume":"119","author":"H Yamaguchi","year":"2013","unstructured":"Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer. 2013;119(18):3354\u201358.","journal-title":"Cancer."},{"issue":"19","key":"9388_CR23","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus Cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36(19):1922\u201329.","journal-title":"J Clin Oncol."},{"issue":"2","key":"9388_CR24","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1245\/s10434-013-3208-y","volume":"21","author":"J Kitayama","year":"2014","unstructured":"Kitayama J, Ishigami H, Yamaguchi H, et al. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. Ann Surg Oncol. 2014;21(2):539\u201346.","journal-title":"Ann Surg Oncol."},{"issue":"Suppl 1","key":"9388_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s10120-016-0684-3","volume":"20","author":"H Ishigami","year":"2017","unstructured":"Ishigami H, Yamaguchi H, Yamashita H, Asakage M, Kitayama J. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer. 2017;20(Suppl 1):128\u201334.","journal-title":"Gastric Cancer."},{"issue":"151(suppl)","key":"9388_CR26","doi-asserted-by":"publisher","first-page":"Abst. 4040","DOI":"10.1200\/JCO.2016.34.15_suppl.4040","volume":"34","author":"Y Fujiwara","year":"2016","unstructured":"Fujiwara Y, Ishigami H, Miwa H, et al. Phase II study of intraperitoneal paclitaxel plus S-1\/oxaliplatin for gastric cancer with peritoneal metastasis: SOX\u2009+\u2009IP PTX trial. J Clin Oncol. 2016;34(15(suppl)):Abst. 4040.","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"9388_CR27","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/jjco\/hys129","volume":"42","author":"S Emoto","year":"2012","unstructured":"Emoto S, Ishigami H, Hidemura A, et al. Complications and management of an implanted intraperitoneal access port system for intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Jpn J Clin Oncol. 2012;42(11):1013\u201319.","journal-title":"Jpn J Clin Oncol."},{"issue":"1","key":"9388_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1477-7800-2-3","volume":"2","author":"RL Harmon","year":"2005","unstructured":"Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005;2(1):3.","journal-title":"Int. Semin. Surg. Oncol."},{"issue":"2","key":"9388_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","volume":"14","author":"Association JGC","year":"2011","unstructured":"Association JGC. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101\u2013112.","journal-title":"Gastric Cancer."},{"issue":"4","key":"9388_CR30","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ejca.2011.12.017","volume":"48","author":"GM Kim","year":"2012","unstructured":"Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer. 2012;48(4):518\u201326.","journal-title":"Eur J Cancer."},{"issue":"1","key":"9388_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 2015;26(1):141\u2013148.","journal-title":"Ann Oncol."},{"issue":"20","key":"9388_CR32","doi-asserted-by":"publisher","first-page":"e15696","DOI":"10.1097\/MD.0000000000015696","volume":"98","author":"C Xiao","year":"2019","unstructured":"Xiao C, Qian J, Zheng Y, et al. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China. Medicine (Baltimore). 2019;98(20):e15696.","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"9388_CR33","doi-asserted-by":"publisher","first-page":"e000130","DOI":"10.1136\/esmoopen-2016-000130","volume":"2","author":"H Satake","year":"2017","unstructured":"Satake H, Miki A, Kondo M, et al. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI). ESMO Open. 2017;2(1):e000130.","journal-title":"ESMO Open."},{"issue":"4","key":"9388_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/jso.21324","volume":"100","author":"Y Yonemura","year":"2009","unstructured":"Yonemura Y, Endou Y, Shinbo M, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol. 2009;100(4):311\u201316.","journal-title":"J Surg Oncol."},{"issue":"13","key":"9388_CR35","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1245\/s10434-011-1770-8","volume":"18","author":"Y Fujiwara","year":"2011","unstructured":"Fujiwara Y, Takiguchi S, Nakajima K, et al. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination. Ann Surg Oncol. 2011;18(13):3726\u201331.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"9388_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ygyno.2008.09.041","volume":"112","author":"S Tangjitgamol","year":"2009","unstructured":"Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P. Interval debulking surgery for advanced epithelial ovarian cancer: a Cochrane systematic review. Gynecol Oncol. 2009;112(1):257\u201364.","journal-title":"Gynecol. Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09388-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-09388-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09388-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T09:23:42Z","timestamp":1623057822000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-09388-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["9388"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-09388-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,3]]},"assertion":[{"value":"6 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest related to this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}